London UK, 1 October 2024 – AstronauTx Ltd (“AstronauTx”), a biotechnology company developing novel treatments for Alzheimer’s disease and other neurodegenerative disorders, today announces the appointment of Dr Jane Rhodes, PhD, MBA, as Chief Executive Officer (CEO) and member of the Board, and Magnus Ivarsson as Chief Translation and Early Development Officer.
https://astronautx.bio/wp-content/uploads/2023/09/AstronauTx_Logo_RGB_REV_Green.svg00provalenshttps://astronautx.bio/wp-content/uploads/2023/09/AstronauTx_Logo_RGB_REV_Green.svgprovalens2024-10-01 08:30:242024-10-01 08:30:24AstronauTx appoints Jane Rhodes as Chief Executive Officer and Expands Executive Team
London UK, 9 October 2023 – AstronauTx Ltd. (“AstronauTx”), a biotech company developing novel treatments for Alzheimer’s disease and other neurodegenerative disorders, today announced the completion of a £48 million ($61 million) Series A financing.
https://astronautx.bio/wp-content/uploads/2023/09/AstronauTx_Logo_RGB_REV_Green.svg00provalenshttps://astronautx.bio/wp-content/uploads/2023/09/AstronauTx_Logo_RGB_REV_Green.svgprovalens2023-10-09 08:00:032024-09-27 09:57:55AstronauTx closes £48 million ($61 million) Series A financing to create new treatments for Alzheimer’s disease
Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on the discovery and development of medicines modulating ion channels, today announced a new research collaboration with AstronauTx in Alzheimer’s disease. Saniona may receive up to SEK 1.9 billion ($177 million) in milestone payments as well as royalties on worldwide net sales of resulting products under the collaboration.
https://astronautx.bio/wp-content/uploads/2023/09/AstronauTx_Logo_RGB_REV_Green.svg00provalenshttps://astronautx.bio/wp-content/uploads/2023/09/AstronauTx_Logo_RGB_REV_Green.svgprovalens2023-07-17 08:00:302023-10-06 11:16:08Saniona enters into collaboration agreement with AstronauTx in Alzheimer’s disease
Awards
Most Significant Contribution to the Mediscience Sector Award
June 2024, European Mediscience Awards website – read more
Primary R&D Company – ON Awards
April 2024, One Nucleus Annual Awards website – read more
We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
Other external services
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
Privacy Policy
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
AstronauTx appoints Jane Rhodes as Chief Executive Officer and Expands Executive Team
London UK, 1 October 2024 – AstronauTx Ltd (“AstronauTx”), a biotechnology company developing novel treatments for Alzheimer’s disease and other neurodegenerative disorders, today announces the appointment of Dr Jane Rhodes, PhD, MBA, as Chief Executive Officer (CEO) and member of the Board, and Magnus Ivarsson as Chief Translation and Early Development Officer.
AstronauTx closes £48 million ($61 million) Series A financing to create new treatments for Alzheimer’s disease
London UK, 9 October 2023 – AstronauTx Ltd. (“AstronauTx”), a biotech company developing novel treatments for Alzheimer’s disease and other neurodegenerative disorders, today announced the completion of a £48 million ($61 million) Series A financing.
Saniona enters into collaboration agreement with AstronauTx in Alzheimer’s disease
Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on the discovery and development of medicines modulating ion channels, today announced a new research collaboration with AstronauTx in Alzheimer’s disease. Saniona may receive up to SEK 1.9 billion ($177 million) in milestone payments as well as royalties on worldwide net sales of resulting products under the collaboration.